Wrocław, Poland, December 19, 2022. - Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment of cancer and autoimmune diseases, today announces that the company's Chief Executive Officer, Dr. Tom Shepherd, and Chief Scientific Officer, Dr. Michal Walczak, will be in San Francisco during the J.P. Morgan 41st Annual Healthcare Conference from January 9-12, 2023 to meet with investors and potential strategic partners.
To request a one-on-one meeting with the Captor Therapeutics management team, please contact us at investor.relationshw@captortherapeutics.com
About Captor Therapeutics
Captor Therapeutics is a biopharmaceutical company dedicated to using targeted protein degradation (TPD) technology to discover and develop breakthrough drugs for diseases deemed as medically uncurable. TPD is a revolutionary approach to developing new drugs that can target new molecular targets considered "untreatable" using classical drug development methods and provide additional treatment options for diseases where existing drugs do not provide optimal medical benefit. Captor is currently developing treatments for undertreated serious conditions, including malignancies and autoimmune diseases.
For more information on Captor Therapeutics, visit: http://www.captortherapeutics.com
LinkedIn: @CaptorTherapeutics
Twitter: @CaptorTherapeu1
Media and investor contacts:
|
Polish Media and Investor relations: Point of View Bartosz Sawulski +48 694 400 787 |
International Investor Relations: LifeSci Advisors Guillaume van Renterghem +41 (0)76 735 01 31 |
